ADMA
Price
$17.93
Change
-$0.35 (-1.91%)
Updated
Jul 7, 03:35 PM (EDT)
Capitalization
4.36B
30 days until earnings call
RYTM
Price
$65.94
Change
+$0.17 (+0.26%)
Updated
Jul 7, 01:11 PM (EDT)
Capitalization
4.18B
29 days until earnings call
Interact to see
Advertisement

ADMA vs RYTM

Header iconADMA vs RYTM Comparison
Open Charts ADMA vs RYTMBanner chart's image
ADMA Biologics
Price$17.93
Change-$0.35 (-1.91%)
Volume$763
Capitalization4.36B
Rhythm Pharmaceuticals
Price$65.94
Change+$0.17 (+0.26%)
Volume$500
Capitalization4.18B
ADMA vs RYTM Comparison Chart in %
Loading...
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADMA vs. RYTM commentary
Jul 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADMA is a StrongBuy and RYTM is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 08, 2025
Stock price -- (ADMA: $18.28 vs. RYTM: $65.77)
Brand notoriety: ADMA and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADMA: 31% vs. RYTM: 102%
Market capitalization -- ADMA: $4.36B vs. RYTM: $4.18B
ADMA [@Biotechnology] is valued at $4.36B. RYTM’s [@Biotechnology] market capitalization is $4.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADMA’s FA Score shows that 2 FA rating(s) are green whileRYTM’s FA Score has 0 green FA rating(s).

  • ADMA’s FA Score: 2 green, 3 red.
  • RYTM’s FA Score: 0 green, 5 red.
According to our system of comparison, ADMA is a better buy in the long-term than RYTM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADMA’s TA Score shows that 5 TA indicator(s) are bullish while RYTM’s TA Score has 6 bullish TA indicator(s).

  • ADMA’s TA Score: 5 bullish, 3 bearish.
  • RYTM’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, RYTM is a better buy in the short-term than ADMA.

Price Growth

ADMA (@Biotechnology) experienced а -0.65% price change this week, while RYTM (@Biotechnology) price change was +7.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.35%. For the same industry, the average monthly price growth was +13.82%, and the average quarterly price growth was -0.82%.

Reported Earning Dates

ADMA is expected to report earnings on Aug 06, 2025.

RYTM is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (+5.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ADMA($4.36B) and RYTM($4.18B) have the same market capitalization . RYTM YTD gains are higher at: 17.488 vs. ADMA (6.589). ADMA has higher annual earnings (EBITDA): 161M vs. RYTM (-145.8M). RYTM has more cash in the bank: 314M vs. ADMA (71.6M). RYTM has less debt than ADMA: RYTM (4.06M) vs ADMA (82M). ADMA has higher revenues than RYTM: ADMA (459M) vs RYTM (137M).
ADMARYTMADMA / RYTM
Capitalization4.36B4.18B104%
EBITDA161M-145.8M-110%
Gain YTD6.58917.48838%
P/E Ratio21.76N/A-
Revenue459M137M335%
Total Cash71.6M314M23%
Total Debt82M4.06M2,018%
FUNDAMENTALS RATINGS
ADMA vs RYTM: Fundamental Ratings
ADMA
RYTM
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
97
Overvalued
PROFIT vs RISK RATING
1..100
1734
SMR RATING
1..100
15100
PRICE GROWTH RATING
1..100
5542
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADMA's Valuation (75) in the Biotechnology industry is in the same range as RYTM (97). This means that ADMA’s stock grew similarly to RYTM’s over the last 12 months.

ADMA's Profit vs Risk Rating (17) in the Biotechnology industry is in the same range as RYTM (34). This means that ADMA’s stock grew similarly to RYTM’s over the last 12 months.

ADMA's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for RYTM (100). This means that ADMA’s stock grew significantly faster than RYTM’s over the last 12 months.

RYTM's Price Growth Rating (42) in the Biotechnology industry is in the same range as ADMA (55). This means that RYTM’s stock grew similarly to ADMA’s over the last 12 months.

RYTM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ADMA (100). This means that RYTM’s stock grew similarly to ADMA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADMARYTM
RSI
ODDS (%)
Bullish Trend 5 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 5 days ago
86%
Bearish Trend 5 days ago
90%
Momentum
ODDS (%)
Bullish Trend 5 days ago
87%
Bullish Trend 5 days ago
83%
MACD
ODDS (%)
Bearish Trend 5 days ago
73%
Bullish Trend 5 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
78%
Bullish Trend 5 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
76%
Bullish Trend 5 days ago
75%
Advances
ODDS (%)
Bullish Trend 5 days ago
88%
Bullish Trend 6 days ago
79%
Declines
ODDS (%)
Bearish Trend 18 days ago
75%
Bearish Trend 12 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
85%
Bearish Trend 5 days ago
82%
Aroon
ODDS (%)
N/A
Bullish Trend 5 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PMVRX19.230.28
+1.48%
Putnam Sustainable Future R
APDMX36.790.32
+0.88%
Artisan Mid Cap Advisor
SPSAX19.690.15
+0.77%
Sterling Capital Behav Sm Cp Val Eq A
GSMCX38.110.22
+0.58%
Goldman Sachs Mid Cap Value Instl
VHYAX40.950.23
+0.56%
Vanguard High Dividend Yield Index Adm

ADMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with TARS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then TARS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
+0.77%
TARS - ADMA
42%
Loosely correlated
+1.73%
IMTX - ADMA
42%
Loosely correlated
+2.15%
ACLX - ADMA
40%
Loosely correlated
+1.24%
RYTM - ADMA
39%
Loosely correlated
-1.72%
ROIV - ADMA
38%
Loosely correlated
+0.18%
More

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with CRNX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
-1.72%
CRNX - RYTM
46%
Loosely correlated
+1.22%
ERAS - RYTM
46%
Loosely correlated
-0.69%
RVMD - RYTM
45%
Loosely correlated
+1.83%
DNLI - RYTM
45%
Loosely correlated
-1.41%
IDYA - RYTM
44%
Loosely correlated
+0.82%
More